MNPR analyst estimates
Monopar Therapeutics (MNPR) analyst ratings, the average price target and its range, and every firm's latest call.
MNPR analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Sep 11, 2026 | Barclays | Monopar Therapeutics price target raised to $145 from $128 at Barclays | $145.00 |
| Aug 17, 2026 | Morgan Stanley | Monopar Therapeutics price target raised to $130 from $115 at Morgan Stanley | $130.00 |
| Aug 13, 2026 | Cantor Fitzgerald | Monopar Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald | $119.00 |
| Aug 13, 2026 | Barclays | Monopar Therapeutics price target raised to $128 from $125 at Barclays | $128.00 |
| Aug 12, 2026 | BTIG | Monopar Therapeutics price target raised to $133 from $117 at BTIG | $133.00 |
| Jul 23, 2026 | UBS | Monopar Therapeutics (MNPR) PT Raised to $125 at H.C. Wainwright | $125.00 |
| Jul 22, 2026 | H.C. Wainwright | Monopar price target raised to $125 from $105 at H.C. Wainwright | $125.00 |
| Jun 30, 2026 | BTIG | Monopar Therapeutics (MNPR) PT Raised to $117 at BTIGMember Login | $117.00 |
| Jun 29, 2026 | UBS | H.C. Wainwright Reiterates Buy Rating on Monopar Therapeutics (MNPR) | $105.00 |
| Jun 2, 2026 | Piper Sandler | H.C. Wainwright Reiterates Buy Rating on Monopar Therapeutics (MNPR) | $105.00 |
| Jan 9, 2026 | Morgan Stanley | Monopar Therapeutics initiated with an Overweight at Morgan Stanley | $115.00 |
| Nov 14, 2025 | Raymond James | Raymond James Downgrades Monopar Therapeutics (MNPR) to Outperform | $123.00 |
| Oct 13, 2025 | Barclays | Monopar Therapeutics initiated with an Overweight at Barclays | $125.00 |
| Oct 6, 2025 | Raymond James | Monopar Therapeutics price target raised to $142 from $80 at Raymond James | $142.00 |
| Oct 2, 2025 | Oppenheimer | Monopar Therapeutics price target raised to $115 from $77 at Oppenheimer | $115.00 |
- 8 firms rate MNPR: 7 buy, 1 hold, 0 sell.
- The average price target is $126.00 from 7 analysts, from $105.00 to $145.00.
Updated 2026-11-02 17:13 UTC